Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Ca...

Identification & Treatment of Patients w/ HR+, HER2- #EarlyBreastCancer at a High Risk of RecurrenceПодробнее

Session 6: Treatment selection for patients with low and equivocal ER status (Hope Rugo, USA)Подробнее

Breast Cancer & HRT: the complex relationship between hormones & cancer | Felice Gersh, MDПодробнее

Virtual Pink House: Understanding HER2 Breast Cancer RecurrenceПодробнее

PENELOPE-B: palbociclib with endocrine therapy in HR+, HER2-negative breast cancerПодробнее

BBCC 2024 - Hall B - Day 2 - Challenges in Management of Breast Cancer 1Подробнее

Factors Associated With Poor Prognosis in Patients With HR+, HER2- #MetastaticBreastCancerПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее

Understanding the Impact of Heterogeneity on Prognosis in HR+, HER2- Metastatic Breast CancerПодробнее

Video Viewpoint on Clinical Debates in Breast Cancer -Advanced ER-Positive Disease Part 1Подробнее

Advances in Management of Hormone Receptor positive Breast cancerПодробнее

Locally Advanced HER2+ Breast CancerПодробнее

Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancerПодробнее

Targeted Therapy for HER2-positive Breast Cancer AnimationПодробнее

ROSALINE: endocrine therapy and entrectinib in HR+/HER2- ILBCПодробнее

PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BCПодробнее

Identifying BPD Risk | Early Intervention InsightsПодробнее

The Role of AI and TDXD in Advancing HER2 Positive Breast Cancer Care – Dr. Eleonora TeplinskyПодробнее

The Interpersonal Problems in Borderline Personality Disorder #shortsПодробнее